Clariborol Intermediates (CAS 1187188-60-8) | High-Purity API Building Blocks for Psoriasis & Dermatitis Drug Development?

?Overview?

Clariborol Intermediates are ?pharmaceutical-grade chemical compounds? essential for synthesizing ?Crisaborole?, a non-steroidal PDE4 inhibitor approved for ?psoriasis and atopic dermatitis treatment??12. With ≥98% purity (HPLC/GC-MS validated), these intermediates meet stringent ?USP/EP standards? for API manufacturing and preclinical research?12.

?Key Applications?

?? ?Drug Development?:

• Critical precursors for 

  ?Crisaborole (Eucrisa?)?

  , targeting inflammatory skin disorders?23.

• Used in 

  ?PDE4 inhibitor optimization?

   to enhance drug efficacy and safety profiles?13.

?? ?Research Use?:

• Supports 

  ?dermatology studies?

  , including keratinocyte modulation and anti-inflammatory assays?23.

?Product Specifications?

? ?Purity?: ≥98% (certified by COA with residual solvent <50 ppm)?12.
? ?Form?: White to off-white crystalline powder?2.
?? ?Packaging?: Bulk quantities (1-25 kg) or lab-scale units (100 g, 500 g)?13.
??? ?Storage?: Stable for 24 months at 2-8°C in airtight, light-resistant containers?24.

?Quality & Compliance?

?? ?Pharmaceutical Compliance?: Manufactured under GMP guidelines for API intermediates?24.
?? ?Analytical Reports?: Includes heavy metals (<10 ppm), microbial limits, and chiral purity testing?24.

?Supply Benefits?

?? ?Global Availability?: Ready stock in EU, US, and Asia warehouses for fast delivery?13.
?? ?Custom Solutions?: Tailored packaging (e.g., nitrogen-sealed vials) and documentation support?23.

?Keywords?: Clariborol Intermediates CAS 1187188-60-8, Crisaborole API Precursors, Psoriasis Drug R&D, PDE4 Inhibitor Synthesis, GMP Pharmaceutical Intermediates?12.